UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Volltextzugriff (PDF)

Prognostic significance of left ventricular mass change during treatment of hypertension

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (19), p.2350

2004

Volltextzugriff (PDF)

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

JAMA : the journal of the American Medical Association, 2004-11, Vol.292 (19), p.2343

2004

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.1004-1010

2002

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.705-711

2005

Volltextzugriff (PDF)

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

JAMA : the journal of the American Medical Association, 2002-09, Vol.288 (12), p.1491

2002

Volltextzugriff (PDF)

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

Circulation (New York, N.Y.), 2003-08, Vol.108 (6), p.684-690

2003

Volltextzugriff (PDF)

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy

Journal of hypertension, 2002-09, Vol.20 (9), p.1855-1864

2002

Volltextzugriff (PDF)

Off-Label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII

Journal of intensive care medicine, 2006-07, Vol.21 (4), p.247-248

2006

Volltextzugriff (PDF)

Clinical Trial Educator program – a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial

Clinical trials (London, England), 2012-06, Vol.9 (3), p.358-366

2012

Volltextzugriff (PDF)

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Annals of internal medicine, 2003-08, Vol.139 (3), p.169

2003

Volltextzugriff (PDF)

Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension

The American journal of cardiology, 2001-03, Vol.87 (6), p.721-726

2001

Volltextzugriff (PDF)

The authors reply

Clinical therapeutics, 2001-03, Vol.23 (3), p.517-518

2001

Volltextzugriff (PDF)

Tackling ACE-inhibitor cough

The Lancet (British edition), 1997-12, Vol.350 (9094), p.1854-1855

Aurup, Peter

1997

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation

Journal of the American College of Cardiology, 2005-03, Vol.45 (5), p.705-711

2005

Volltextzugriff (PDF)

Association of left ventricular hypertrophy regression and heart rate reduction with determinants of myocardial oxygen consumption and cardiovascular events: The LIFE study

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.400-400

2003

Volltextzugriff (PDF)

Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.228-228

2003

Volltextzugriff (PDF)

Losartan and renal transplantation

The Lancet (British edition), 1998-03, Vol.351 (9107), p.990-990

1998

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.276-276

2003

Volltextzugriff (PDF)

1085-170 Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A482-A482

2004

Volltextzugriff (PDF)

Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction

BMJ, 1993-09, Vol.307 (6904), p.585-587

International edition, 1993

Volltextzugriff (PDF)

Magnesium deficiency in patients with ischemic heart disease with and without acute myocardial infarction uncovered by an intravenous loading test

Archives of internal medicine (1960), 1988-02, Vol.148 (2), p.329

1988

Volltextzugriff (PDF)

The effect of intravenous magnesium therapy on serum and urine levels of potassium, calcium, and sodium in patients with ischemic heart disease, with and without acute myocardial infarction

Archives of internal medicine (1960), 1988-08, Vol.148 (8), p.1801

1988

Volltextzugriff (PDF)

Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study

Archives of internal medicine (1960), 1989-05, Vol.149 (5), p.1050

1989

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Life Sciences & Biomedicine
(15)
Middle Aged
(15)
Science & Technology
(15)
Aged
(14)
Biological And Medical Sciences
(14)
Female
(14)
Male
(14)
Medical Sciences
(14)
Antihypertensive Agents - Therapeutic Use
(12)
Losartan - Therapeutic Use
(12)
Double-Blind Method
(10)
Hypertension - Drug Therapy
(10)
Atenolol - Therapeutic Use
(9)
General & Internal Medicine
(9)
Medicine, General & Internal
(9)
Pharmacology. Drug Treatments
(9)
Medicin Och Hälsovetenskap
(8)
Cardiovascular System
(7)
Hypertension
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Prognostic significance of left ventricular mass change during treatment of hypertension

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation : The losartan intervention for end point reduction in hypertension (LIFE) study

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy

Off-Label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII

Clinical Trial Educator program – a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension

The authors reply

Tackling ACE-inhibitor cough

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation

Association of left ventricular hypertrophy regression and heart rate reduction with determinants of myocardial oxygen consumption and cardiovascular events: The LIFE study

Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study

Losartan and renal transplantation

Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study

1085-170 Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy

Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction

Magnesium deficiency in patients with ischemic heart disease with and without acute myocardial infarction uncovered by an intravenous loading test

The effect of intravenous magnesium therapy on serum and urine levels of potassium, calcium, and sodium in patients with ischemic heart disease, with and without acute myocardial infarction

Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study

Suchergebnisse filtern